Pliant Therapeutics to Present FORTIFY Trial Findings at ESMO Congress 2026
News related to:Pliant Therapeutics · 1 min read
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /CourierPR/ -- Pliant Therapeutics, a clinical-stage biopharmaceutical company, is set to present new findings at the upcoming European Society for Medical Oncology (ESMO) Congress 2026, which will take place in Madrid, Spain, from October 23-27, 2026. The presentation will focus on the ongoing Phase 1b indication expansion trial of PLN-101095, a small molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins.
The trial, known as FORTIFY (NCT06270706), is evaluating the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab. The study is enrolling patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Specifically, the trial is divided into three cohorts: non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden, and clear cell renal cell carcinoma.
Timothy A. Yap, MBBS, Ph.D., from the University of Texas, M.D. Anderson Cancer Center, will present the findings on Friday, October 23, 2026, from 3:15 to 4:00 p.m. Central European Summer Time (CEST) in Hall 5, Poster 1082TiP.
PLN-101095 is being investigated in FORTIFY as a potential treatment for ICI-refractory advanced or metastatic solid tumors. Patients in the trial will first receive PLN-101095 dosed at 1,000 mg twice daily for 14 days as monotherapy. Following this, pembrolizumab will be added as combination therapy. The trial is part of Pliant Therapeutics' broader strategy to develop integrin-based therapeutics for the treatment of various cancers.
Pliant Therapeutics, headquartered in the United States, is focused on the discovery and development of integrin-based therapeutics. The company's lead program, PLN-101095, is being evaluated in a Phase 1b indication expansion trial, with the goal of expanding its use in patients who have not responded to existing immunotherapy treatments.